FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3185339026> ?p ?o ?g. }

• W3185339026 endingPage "162" @default.
• W3185339026 startingPage "149" @default.
• W3185339026 abstract "Background: Community-acquired pneumonia (CAP) is a significant global health concern. Pathogens causing CAP demonstrate increasing resistance to commonly prescribed empiric treatments. Resistance in Streptococcus pneumoniae, the most prevalent bacterial cause of CAP, has been increasing worldwide, highlighting the need for improved antibacterial agents. Lefamulin, a novel pleuromutilin, is a recently approved therapeutic agent highly active against many lower respiratory tract pathogens. However, to date minimal data are available to describe the in vitro activity of lefamulin against bacterial isolates associated with CAP. Methods: Common bacterial causes of CAP obtained from both lower respiratory and blood specimen isolates cultured by hospital laboratories across Canada were submitted to the annual CANWARD study’s coordinating laboratory in Winnipeg, Canada, from January 2015 to October 2018. A total of 876 bacterial isolates were tested against lefamulin and comparator agents using the Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution method, and minimum inhibitory concentrations (MICs) were interpreted using accepted breakpoints. Results: All S. pneumoniae isolates tested from both respiratory (n = 315) and blood specimens (n = 167) were susceptible to lefamulin (MIC ≤0.5 μg/mL), including isolates resistant to penicillins, clarithromycin, doxycycline, and trimethoprim–sulfamethoxazole. Lefamulin also inhibited 99.0% of Haemophilus influenzae isolates (regardless of β-lactamase production) (99 specimens; MIC ≤2 μg/mL) and 95.7% of methicillin-susceptible Staphylococcus aureus (MSSA) (MIC ≤0.25 μg/mL; 70 specimens) at their susceptible breakpoints. Conclusions: Lefamulin demonstrated potent in vitro activity against all respiratory isolates tested and may represent a significant advancement in empiric treatment options for CAP." @default.
• W3185339026 created "2021-08-02" @default.
• W3185339026 creator A5014708830 @default.
• W3185339026 creator A5034066865 @default.
• W3185339026 creator A5040054328 @default.
• W3185339026 creator A5048766617 @default.
• W3185339026 creator A5061522332 @default.
• W3185339026 creator A5071438112 @default.
• W3185339026 creator A5090227234 @default.
• W3185339026 date "2021-07-01" @default.
• W3185339026 modified "2023-10-16" @default.
• W3185339026 title "In vitro susceptibility of common bacterial pathogens causing respiratory tract infections in Canada to lefamulin, a new pleuromutilin" @default.
• W3185339026 cites W142414516 @default.
• W3185339026 cites W1522309498 @default.
• W3185339026 cites W1988516563 @default.
• W3185339026 cites W2098589044 @default.
• W3185339026 cites W2122687703 @default.
• W3185339026 cites W2144705366 @default.
• W3185339026 cites W2345894311 @default.
• W3185339026 cites W2517473827 @default.
• W3185339026 cites W2540925660 @default.
• W3185339026 cites W2551731940 @default.
• W3185339026 cites W2558544919 @default.
• W3185339026 cites W2607163536 @default.
• W3185339026 cites W2809835222 @default.
• W3185339026 cites W2902091949 @default.
• W3185339026 cites W2906691128 @default.
• W3185339026 cites W2909191638 @default.
• W3185339026 cites W2912632549 @default.
• W3185339026 cites W2912934371 @default.
• W3185339026 cites W2913128833 @default.
• W3185339026 cites W2927629499 @default.
• W3185339026 cites W2969252003 @default.
• W3185339026 cites W2969801331 @default.
• W3185339026 cites W2977132187 @default.
• W3185339026 cites W2977322360 @default.
• W3185339026 cites W2982145215 @default.
• W3185339026 cites W3001005446 @default.
• W3185339026 cites W3041447078 @default.
• W3185339026 cites W3083401945 @default.
• W3185339026 cites W4205997549 @default.
• W3185339026 cites W4235175266 @default.
• W3185339026 cites W4244538299 @default.
• W3185339026 doi "https://doi.org/10.3138/jammi-2020-0043" @default.
• W3185339026 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36341032" @default.
• W3185339026 hasPublicationYear "2021" @default.
• W3185339026 type Work @default.
• W3185339026 sameAs 3185339026 @default.
• W3185339026 citedByCount "0" @default.
• W3185339026 crossrefType "journal-article" @default.
• W3185339026 hasAuthorship W3185339026A5014708830 @default.
• W3185339026 hasAuthorship W3185339026A5034066865 @default.
• W3185339026 hasAuthorship W3185339026A5040054328 @default.
• W3185339026 hasAuthorship W3185339026A5048766617 @default.
• W3185339026 hasAuthorship W3185339026A5061522332 @default.
• W3185339026 hasAuthorship W3185339026A5071438112 @default.
• W3185339026 hasAuthorship W3185339026A5090227234 @default.
• W3185339026 hasBestOaLocation W31853390261 @default.
• W3185339026 hasConcept C126322002 @default.
• W3185339026 hasConcept C176947019 @default.
• W3185339026 hasConcept C2776012195 @default.
• W3185339026 hasConcept C2776345407 @default.
• W3185339026 hasConcept C2776551000 @default.
• W3185339026 hasConcept C2776925733 @default.
• W3185339026 hasConcept C2779425571 @default.
• W3185339026 hasConcept C2779489039 @default.
• W3185339026 hasConcept C2780728791 @default.
• W3185339026 hasConcept C2780950330 @default.
• W3185339026 hasConcept C2781253189 @default.
• W3185339026 hasConcept C4937899 @default.
• W3185339026 hasConcept C501593827 @default.
• W3185339026 hasConcept C523546767 @default.
• W3185339026 hasConcept C534529494 @default.
• W3185339026 hasConcept C54355233 @default.
• W3185339026 hasConcept C71924100 @default.
• W3185339026 hasConcept C86803240 @default.
• W3185339026 hasConcept C89423630 @default.
• W3185339026 hasConceptScore W3185339026C126322002 @default.
• W3185339026 hasConceptScore W3185339026C176947019 @default.
• W3185339026 hasConceptScore W3185339026C2776012195 @default.
• W3185339026 hasConceptScore W3185339026C2776345407 @default.
• W3185339026 hasConceptScore W3185339026C2776551000 @default.
• W3185339026 hasConceptScore W3185339026C2776925733 @default.
• W3185339026 hasConceptScore W3185339026C2779425571 @default.
• W3185339026 hasConceptScore W3185339026C2779489039 @default.
• W3185339026 hasConceptScore W3185339026C2780728791 @default.
• W3185339026 hasConceptScore W3185339026C2780950330 @default.
• W3185339026 hasConceptScore W3185339026C2781253189 @default.
• W3185339026 hasConceptScore W3185339026C4937899 @default.
• W3185339026 hasConceptScore W3185339026C501593827 @default.
• W3185339026 hasConceptScore W3185339026C523546767 @default.
• W3185339026 hasConceptScore W3185339026C534529494 @default.
• W3185339026 hasConceptScore W3185339026C54355233 @default.
• W3185339026 hasConceptScore W3185339026C71924100 @default.
• W3185339026 hasConceptScore W3185339026C86803240 @default.
• W3185339026 hasConceptScore W3185339026C89423630 @default.
• W3185339026 hasIssue "2" @default.
• W3185339026 hasLocation W31853390261 @default.

• next